Drugmakers hiked prices 1k% in price-fixing scheme, states allege
arstechnica.com
arstechnica.com
So, force them to reset prices. Don't slap them on the wrists with easily paid fines. Make them reset prices.
The current practice is to mark drugs up sky high and rebate the prices. Maybe someone can educate me, but it looks very similar to money laundering IMHO.
Interestingly, the US has some of the cheapest generic drug prices in the world due to the level of competition. I had read that for some generic companies, they make almost 100% of their profit by wining patent cases. Once competition ramps up, their margin is razor thin.
So based on that, I guess it’s not that surprising companies would collide in order to improve margins.
My mom, who lives in a southeast asian country, came to visit me in the US last month and I asked her to buy generic antibiotics; ear drops; artificial tear drops; generic antihistamines; and they all are much cheaper than what I would have paid here (and are equally effective in a way that I've been weathering fine in this allergy season with these drugs). My significant other, who is from the same country as I, is a medical resident in the US and she still orders meds from her parents.
This isn't the whole story; east Asian manufacturers also produce cheaper products, for a bunch of reasons from lower costs to lower regulation to lower profits. And it's notably not the case for non-essential, non-basic medicines (e.g. most psychiatric meds), expensive new generics not used abroad, and certain other high-demand generics like insulin. Those are either expensive everywhere, or more expensive in the US than other wealthy countries and largely unused in poorer countries. (How all this relates to your story depends a lot on whether we're talking about Bangladesh or Taiwan.)
But as far as generic antibiotics or antihistamines, it's going to be hard to separate "US manufacturers overcharge" from "US manufacturers sell cheap abroad".
Not everyone agrees with that statement.
First of all, purchasing negotiations are all secret. US manufactures could very well be saying one thing, and doing another.
Donald Trump said something along those lines some time ago, calling EU "Freeloaders". There is a Wall Street Journal article echoing his comments.
Here's an answer from EU's Health Commissioner Vytenis Andriukaitis:
https://sciencebusiness.net/news/drug-prices-row-eu-health-c...
tl;dr: according to him, Trump was just lying.
What I'm talking about is medicines that are donated, sold with differential pricing, or assigned 'voluntary licenses' to increase medical access in underdeveloped countries. Voluntary license medicines are required to be produced with substantially different appearances from their developed-nation analogues, specifically so that they won't be exported back to undercut those products.
All of those programs are fundamentally good things which save lives, but they lead to some pretty strange outcomes and in turn strange reporting. It can be vastly cheaper to obtain a medicine in an underdeveloped country with supply shortages than in the first world, and that sometimes also prompts articles saying that such-and-such a medicine "only costs 10 cents in other countries!" As far as I know, this is mostly an issue in the US; most other high-differential-price countries have socialized healthcare or other functional solutions like Singapore's, but the US has a lot of extremely poor people who end up paying much higher prices than equally impoverished people abroad.
https://apps.who.int/medicinedocs/documents/s17815en/s17815e...
By comparison, the United States has historically had low generic drug prices and high rates of generic drug use (84% in 2013), but has in recent years experienced sharp price increases for some off‐patent products.[1]
It applies to almost all real-life markets. It's so standard that we don't even notice it happening, and focus on the exceptions. There is no level of economics you can reach where "competition drives down prices" stops being taken seriously; Nobel-winning left-wing economists like Stiglitz and Krugman accept that as true and relevant. So does Marx(!), who focuses on how lower costs are achieved at the expense of workers rather than capital holders.
Restaurants run at effectively zero margin. Lawn chairs and pencils and window blinds sell for essentially the cost of manufacturing and distribution. Even complex services like VOIP calling have moved from high profitable industries to "essentially free". Markets aren't inherently noble any more than they're inherently evil, but a major part of their value is that price-fixing hardly ever works.
Without appreciating that, we lose sight of just how strange healthcare (and college, and housing) are. When prices stay far above costs despite what presents itself as competition, there's something significant happening that deserves more attention.
Broadly, I've thought that high drug prices in the US stem from a mix of our bizarre insurance system (which rewards 'ambitious' pricing) and regulation. For name-brand drugs, that's largely patent protections, but even for generics it happens via process patents, high filing-fee barriers to enter markets, and regulatory delays to start production. (See e.g. here: https://slatestarcodex.com/2019/04/30/buspirone-shortage-in-...)
I still believe those things are issues. But this story has pushed me to revise how much I think those things matter relative to outright price manipulation. And if the answer is (as I suspect) that clumsy regulation raises costs some everywhere, but gouging raises costs massively for some drugs, then the question of how to fight both problems at once is exceedingly difficult. The only way to escape these sorts of tradeoffs is usually "make better regulations", and it's not clear how we make that happen.
Take 4 or 5 of these criminals, strip them of their fortunes, let the press take many pictures of them handcuffed and going to jail, where they will be for 10 years. Also, force the companies to price the drugs accordingly.
If we repeat this enough, I'm sure the problem will magically solve itself and suddenly the companies will be able to cope with clumsy regulation just fine.
There was recently a story on HN of a journalist's home raided to identify his source. Perhaps that is the kind of system abuse that is called for - sending SWAT teams to the homes of each of the CEOs, board-members, and major shareholders, and ransacking them for any signs of wrongdoing, while holding the accused in handcuffs.
It happens every day to regular people for non-violent crimes in the US. Why should the rich have a different law-enforcement system? Yet this call for equal treatment sounds almost extremist...